MINNEAPOLIS, and BEVERLY HILLS, Calif., Aug. 5, 2014 /PRNewswire/ -- ViaDerma, Inc.
(OTCQB: VDRM), a biotechnology licensing company committed to
bringing new products quickly to the pharmaceutical industry
through innovative research and development, and The Brewer Group,
Inc. (TBG), a diversified global investment advisory firm, today
announced a new strategic partnership. TBG will expand ViaDerma's
business development and marketing efforts at home and abroad to
grow interest in ViaDerma's patent-pending pharmaceutical delivery
system, which allows for rapid transdermal transfer of active
ingredients and immediate relief of symptoms.
ViaDerma licenses products in fields of medicine ranging from
infectious disease treatments to stem-cell therapy. Pharmaceutical
companies seeking more efficient methods for delivering their
products to patients will have new access to solutions worldwide,
as The Brewer Group, Inc. and ViaDerma, Inc. leverage TBG's vast
network to pave the way for new strategic business alliances and
expand the range of the breakthrough rapid delivery of nutrients
and medicines using ViaDerma's technology.
ViaDerma continues to develop new applications for its
trade-secret Rapid Active Ingredient Delivery System (RAIDS), and
founder Dr. Christopher Otiko
emphasizes its extreme versatility. "The speed of the RAIDS method
for pharmaceutical distribution and the wide variety of products
that can utilize it will allow medical professionals and general
consumers alike to benefit from faster treatment," Dr. Otiko said.
"Products using RAIDS are at the forefront of medical
sophistication and nearly any drug that medical professionals can
administer as a pill can utilize RAIDS for quicker delivery, from
pain relievers to cosmetics. As ViaDerma, Inc. expands, our
partnership with The Brewer Group will combine their experience and
network with our revolutionary technologies to reach ever-larger
audiences."
Using tailored business development strategies including
exclusive access to its extensive network and established
relationships spanning the globe, TBG will reach out to synergetic
companies and partner organizations, explore licensing
opportunities as well as provide ongoing marketing support and
enhance global exposure for ViaDerma's unique technology.
"I'm excited to be working with an organization like ViaDerma,
because their technology represents a fundamental shift in the way
we should expect treatment to progress," The Brewer Group CEO H.E.
Ambassador Jack Brewer said. "What
if patients saw results from antibiotics after just a day of
treatment, instead of a week? People would come to demand that kind
of speed, and TBG is ready to connect ViaDerma Inc. with strategic
partners to meet those expectations."
About ViaDerma, Inc.
ViaDerma, Inc. is a biotechnology licensing company committed to
bringing new products quickly to the pharmaceutical industry
through innovative research and development. ViaDerma licenses
products in the fields of medicine ranging from infectious diseases
to stem-cell therapy. Dr. Christopher
Otiko is the company's founder, and ViaDerma became a
publicly-traded company in 2014. For more information, go to
www.viadermalicensing.com.
About The Brewer Group, Inc.
The Brewer Group (TBG) is a multi-faceted global investment
advisory firm focused on providing tailored services including
capital markets, asset management, specialty finance and business
development for public and private companies as well as
high-profile clientele. TBG leverages its relationships with key
international decision-makers spanning government agencies, private
equity firms, corporations, NPOs, leaders in government, and sports
and entertainment to place TBG in a unique position to execute a
wide range of services around the globe. For further information,
please visit www.thebrewergroup.com.
SOURCE ViaDerma, Inc.
